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Non-small cell lung cancer (NSCLC) is among the most 
common cancers and biggest health care challenges in large 
parts of the world. Patients with locally advanced NSCLC 
comprise a heterogeneous group and many of them have 
unsatisfactory outcomes despite aggressive multimodal 
treatment approaches. Those with stage I disease (no 
distant or lymph node metastases; N0 M0) have the highest 
chance for cure. In the current classification system T-stage 
is based on primary tumor size (T1a max. 2.0 cm, T1b 
2.1-3.0 cm, T2a 3.1-5.0 cm). Tumors larger than 5 cm are 
classified as stage II, even in the absence of lymph node 
metastases. In addition stage I requires that these tumors 
are surrounded by lung or visceral pleura and do not invade 
the main bronchus (1). Such tumors rarely cause any clinical 
symptoms, making early detection at this curable stage both 
challenging and crucial. Screening of high-risk patients 
using low-dose thoracic computed tomography (CT) 
imaging is therefore advocated (2).
The historical gold standard for treatment of stage I 
NSCLC, surgery with lobectomy and systematic hilar and 
mediastinal lymph node dissection as the sole curative 
approach, has recently been challenged by hypofractionated 
stereotactic ablative radiation therapy (SBRT or SABR), due 
to several reports describing high local control, low regional 
failure rates and good disease specific survival. SABR has 
evolved along the same principles that guided successful 
implementation of high-precision stereotactic radiotherapy 
for intracranial targets. Groups from Sweden and Japan, and 
later different European countries and the United States of 
America developed slightly different technical and planning 
approaches (3-6). A common feature was short overall 
treatment time, which is advantageous from a radiobiological 
point of view and convenient for patients. With the ability to 
deliver high biologically effective doses (BED) equivalent to 
more than 100 Gy in conventional 2-Gy fractions regardless 
of equipment and technique, local control rates rise 
considerably above those obtained in historical series, where 
conventional fractionated radiotherapy was administered 
over many weeks (7). Consequently, local progression as 
a major source of treatment failure does not limit survival 
after SABR. A recent multi-institutional analysis reported 
2-year local recurrence (LR) of 4% after SBRT with 
BED >105 Gy as compared to 15% for <105 Gy (P<0.01) (8). 
Longer treatment duration (≥11 elapsed days) was associated 
with a 2-year LR of 14% vs. 4% for ≤10 days (P<0.01). 
After initial uncertainty about the safety of SABR in central 
tumors and prescription of relatively low equivalent doses, 
which resulted in sub-optimal LR, reluctance to treat to 
high BED has decreased and prospective studies have been 
designed (9).
When implementing SABR, for example, in two of the 
authors’ previous departments in Munich and Wuerzburg, 
Germany, around the year 2000, referring physicians almost 
exclusively selected very old patients or those with serious 
comorbidity (10). In other words, most of the irradiated 
patients were not eligible for surgery and some not even 
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for invasive diagnosis, needed to obtain tissue and histology 
confirmation. Due to this selection bias, overall survival 
was not comparable to surgical series. Most patients died 
from cardiovascular and pulmonary comorbidity (as well as 
second primary cancers), not from the irradiated NSCLC. 
After a few years and due to the fact that very few patients 
relapsed, referral patterns changed towards a healthier 
population, also including occasional patients who refused 
surgery. All patients were discussed in multidisciplinary 
tumor boards.
Although initial studies on SABR were heterogeneous 
(comprised of both prospective and retrospective series 
with limited patients numbers, in part without histological 
confirmation of malignancy), the results prompted several 
phase II trials and later, population-based studies and 
propensity-matched analyses, which supported the concept 
of randomized phase III trials in early stage I NSCLC, 
comparing SABR to surgical resection in operable patients. 
The ambitious phase III trials (ACOSOG Z4099, ROSEL, 
STARS) were closed early because of slow accrual. However, 
ROSEL (a Dutch trial) and STARS (an international trial) 
shared similar entry criteria and study design, allowing for 
a pooled analysis. The latter has recently been reported and 
provides the best available evidence at this point in time (11).
Both randomized studies intended to compare overall 
survival of operable stage I NSCLC (T1-2a) treated with 
SABR or lobectomy. In principle, it makes sense to combine 
the small databases from both studies, which have insufficient 
statistical power on their own, in order to provide clinically 
applicable hints and hypotheses. In perspective, the failure 
to accrue patients resembles previous attempts to compare 
surgery and radiotherapy or chemoradiotherapy in other 
scenarios, such as bladder or prostate cancer. It is obviously 
not very appealing to patients and referring clinicians 
if the study arms provide extremely different treatment 
approaches, compared to for example studies where two 
different radiotherapy fractionation regimens or two different 
cytotoxic drug cocktails are tested.
The STARS trial attempted to include 420 patients, 
assuming 82% 3-year overall survival after surgery and a 
hazard ratio of less than 1.66. The inferiority limit for the 
ROSEL study was a hazard ratio of 1.35. In essence, the 
aim was to demonstrate that SABR would provide outcomes 
comparable to invasive treatment. After disappointing 
accrual in the time period 2008-2013 the study groups were 
left with 58 patients from both trials combined. Having said 
that combining both datasets makes sense from a statistical 
point of view (increased statistical power), one has to take a 
closer look at the details. What are the differences between 
the patients included in STARS and ROSEL, respectively? 
How cautiously should we interpret the results? As a matter 
of fact, stratification criteria differed between the studies. 
Patients without histological confirmation but fulfilling 
certain clinical criteria pointing strongly towards NSCLC 
were eligible for the ROSEL but not the STARS trial. 
Follow-up intervals were different (quite large time intervals 
of 6 months for 2 years, then annually in the STARS trial), 
raising the possibility that some of the STARS patients 
might have gone with undetected relapse at the time of 
analysis. The differences in equipment and radiotherapy 
details are probably less important, because sufficient doses 
were prescribed in both trials. STARS relied on CyberKnife 
equipment and implanted fiducial markers for image 
guidance. ROSEL utilized linear accelerators from multiple 
vendors. Three to five fractions were administered. It is also 
known from studies of stereotactic radiosurgery for brain 
metastases that equipment and methodology are not crucial 
determinants of outcome as long as the radiation dose is 
sufficiently high (12).
In both study arms median age was 67 years. Most 
patients had performance status 0 or 1. Other information 
is shown in Table 1. Comorbidity was not reported. 
Median follow-up was 40 months in the SABR group and 
35 months in the surgery group. Median survival was not 
reached for either treatment group. Estimated survival 
favored the SABR group (95% at 3 years compared to 79% 
after surgery), P=0.037, hazard ratio 0.14 (95% confidence 
interval 0.017-1.19). Because of short follow-up relapse 
frequencies are preliminary. No significant differences 
emerged. Only one patient developed LR (treated with 
SABR, salvaged by lobectomy). Regional recurrence was 
Table 1 Comparison between the two study arms
Characteristic 
Study arm
SABR group Surgery group
Number of patients 31 27
Stage
T1a 52% 67%
T1b 35% 30%
T2a 13% 4%
Peripheral
No 6% 11%
Yes 94% 89%
SABR, stereotactic ablative radiation therapy.
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numerically higher in the SABR group (13% vs. 4%) 
without reaching statistical significance. Toxicity after SABR 
was in the expected range (max. grade III in 10% of the 
patients), including dyspnea, cough, fatigue, chest wall pain 
and one incidence of rib fracture. In the surgery group, one 
patient died of surgical complications and one developed 
grade IV dyspnea. Other adverse events included grade III 
dyspnea, infections, chest pain and others resulting in 44% 
of the surgical patients suffering from grade 3-4 treatment-
related adverse events.
Since these results suggest that SABR is better tolerated 
and might lead to better survival, the authors correctly 
stated that SABR can be considered a treatment option 
in operable patients needing a lobectomy, and not only 
a compromise for those the surgeons wont touch. The 
equipoise suggested by the combined analysis of STARS and 
ROSEL justifies efforts for additional randomized trials. 
The latter would be desirable because of the small patient 
numbers and limited follow-up. In reality it is difficult to 
expect better recruitment in the future. The present results 
will definitely not diminish bias and stimulate patients’ 
interest in surgery. It required tremendous effort to prepare 
the study protocols and provide the available data from 
STARS and ROSEL. Unfortunately, recruitment was slow 
and the conclusions therefore weaker than anticipated. 
While highly effective local treatment for small stage I 
NSCLC has become reality, challenges persist regarding 
control of larger tumors with SABR. Maybe combined 
modality treatment will contribute to improved outcomes, 
paralleling the developments in stage III disease. Many 
patients with lung cancer ultimately die from distant 
metastases and therefore, better understanding of the 
processes leading to tumor cell seeding and more effective 
approaches to control metastatic disease are needed. 
Preliminary evidence suggests that combinations of systemic 
and local therapy including SABR should be studied in 
well-designed, sufficiently powered trials, unless widespread 
disease precludes reasonable target volumes (13-16).
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